Hims & Hers Health, Inc. (HIMS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 19, 2026, discloses the entry into a Material Definitive Agreement by Hims & Hers Health, Inc. (the "Company"). The Company, through its wholly-owned subsidiary Horizon BidCo Pty Ltd, has agreed to acquire Eucalyptus (EUC Management Pty Ltd), an Australia-based digital health company operating in Australia, the UK, Germany, Canada, and Japan.
Key Financial Metrics and Transaction Structure
The filing details a proposed acquisition with an aggregate enterprise value of up to approximately $1.15 billion. The consideration structure is as follows:
- Upfront Payments: Approximately $240 million payable upon closing.
- Deferred Payments: Approximately $710 million payable over 18 months in installments.
- Earnout Payments: Up to approximately $200 million, contingent on revenue and adjusted EBITDA targets for fiscal years 2026, 2027, and 2028.
- Equity Settlement Option: The Company may satisfy up to 60% of deferred and earnout payments to certain sellers using Class A common stock.
- Employee Retention: Up to $50 million in restricted stock units (RSUs) to be granted to Target employees, with an additional potential $50 million over four years.
- Debt Facility: Negotiation of a $30 million revolving debt facility to support working capital needs prior to closing.
The filing does not provide current revenue, profit, cash flow, or margin data for the Company or the Target, as this is a transaction announcement rather than a periodic financial report.
Material Changes and Outlook
The primary material change is the strategic expansion into international markets via the acquisition of Eucalyptus. The closing is anticipated to occur during the middle of fiscal year 2026. The transaction is subject to customary closing conditions, including regulatory approvals, key contract consents, and the absence of material adverse changes.
Management commentary is limited to the transaction mechanics. The filing includes standard forward-looking statements regarding the timing of the closing and the satisfaction of conditions, noting that actual results may differ materially from expectations.
Risks and Contingencies
Key risks identified in the filing include:
- Failure to consummate the acquisition in a timely manner or at all.
- Diversion of management attention from ongoing business operations.
- Negative impact on business relationships with customers and suppliers.
- Delays or denial of regulatory approvals from governmental entities.
- Uncertainty regarding the final purchase price due to net debt and working capital adjustments.
Investor Verification Checklist
- Verify the final purchase price after net debt and working capital adjustments are calculated post-closing.
- Monitor the status of regulatory approvals required in Australia, the UK, Germany, Canada, and Japan.
- Assess the dilution impact if the Company exercises its option to settle up to 60% of deferred/earnout payments with equity.
- Review the specific revenue and adjusted EBITDA targets required to trigger the $200 million earnout payments.
- Confirm the terms of the proposed $30 million revolving debt facility and its impact on existing credit agreements.